Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. [electronic resource]
Producer: 20120321Description: 1848-55 p. digitalISSN:- 1539-2864
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Bevacizumab
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Humans
- Intravitreal Injections
- Male
- Middle Aged
- Retina -- pathology
- Retinal Neovascularization -- classification
- Retinal Telangiectasis -- classification
- Retrospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity -- physiology
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.